Research
Hormonal
GLP-1/GIP agonists do not increase overall cancer risk and may reduce incidence of obesity-related cancers (endometrial, ovarian, gastrointestinal) via metabolic improvements, though organ-specific long-term safety remains uncertain.
GLP-1/GIP therapies are not associated with a general increase in cancer risk and may lower risk for obesity-related cancers. However, long-term organ-specific effects are not fully known, so standard cancer screening remains essential.
ModerateQualifiesMEDIUM confidence
Current human evidence does not show a consistent increase in overall cancer risk with these therapies; however, signals are heterogeneous across tumor sites and follow-up remains limited.
Why this rating
Based on observational data and secondary RCT endpoints; lacks dedicated, long-term oncologic trials.
Source
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
Sedat Arslan et al. · Academia oncology. · 2026
DOI 10.20935/acadonco8234
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →